Cumulative (cum) survival of patients from 2 cohorts. (A) Survival of patients with GDF-15 level >7575 pg/mL in the test cohort (Athens) and validation cohort (Pavia). (B) Landmark analysis at 6 months in patients who had a reduction of GDF-15 by ≥25% vs those without a decrease or with an increase in GDF-15 in both cohorts: in the Athens cohort (C) and the Pavia cohort (D).